Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers.
Emily Grist, Peter Dutey-Magni, Marina A Parry, Larissa Mendes, Ashwin Sachdeva, James A Proudfoot, Anis A Hamid, Mazlina Ismail, Sarah Howlett, Stefanie Friedrich, Lia DePaula Oliveira, Laura Murphy, Christopher Brawley, Oluwademilade Dairo, Sharanpreet Lall, Yang Liu, Daniel Wetterskog, Anna Wingate, Karolina Nowakowska, Leila Zakka, Claire L Amos, Nafisah B Atako, Victoria Wang, Hannah L Rush, Robert J Jones, Hing Leung, William R Cross, Silke Gillessen, Chris C Parker, Teresa Marafioti, Alfonso Urbanucci, Matthew Fittall, Edward M Schaeffer, Daniel E Spratt, David Waugh, Thomas Powles, Matthew R Sydes, Felix Y Feng, Daniel M Berney, Mahesh K B Parmar, Noel W Clarke, Elai Davicioni, Tamara L Lotan, Christopher J Sweeney, Louise C Brown, Nicholas D James, Gerhardt Attard
Cell 188(20) 5717-5734.e10
摘要
摘要
Advanced prostate cancers respond to hormone therapy but outcomes vary and no predictive tests exist for informed treatment selection. To identify novel biomarker-treatment pairings, we examined associations between biological pathways and 14-year survival outcomes of patients randomized in practice-changing phase 3 trials (testing docetaxel or abiraterone). We included transcriptome-wide expression signatures and immunohistochemistry markers (Ki-67 and PTEN) on prostate tumors from 1,523 patients (832 metastatic). Tumor androgen receptor signaling is associated with longer survival, whereas increased proliferation predicted shorter survival. In a pre-specified analysis, the previously identified decipher RNA signature was both prognostic and predicted survival benefit from docetaxel for metastatic cancers (biomarker-docetaxel interaction p = 0.039). Additionally, transcriptome-based classification of PTEN inactivation identified tumors more likely to have PTEN protein loss (p = 4 × 10-37) and metabolically perturbed metastatic cancers that had shorter survival with hormone therapies (p < 0.001) but exhibited docetaxel sensitivity (biomarker-docetaxel interaction p = 0.002). Transcriptome classifiers predict docetaxel benefit and could be clinically implemented for improved patient management.
KM 提取结果
0 个 Figure · 0 个 KM 面板